Established as a closed biotechnology initiative focused on the stability profiling of bioactive peptides. Operated under strict NDA to engineer high-purity delivery systems for a private circle of investors.
Internal beta-trials identified significant bioavailability loss in liquid serums. The Scientific Board executed a strategic pivot, mandating a transition to exclusively Lyophilized (Freeze-Dried) formulations to guarantee structural integrity.
Final internal validation of the "Skin Architect" and "MitoCharge" stability profiles. We defined the stringent educational and technological framework required for our future Accredited Partner Operators.
RevoVix Labs transitions from a closed consortium to a commercial B2B entity. Initiation of the Accredited Partner Program, granting select clinics access to our proprietary US-engineered protocols.